Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development

Míreanna comhchosúla

• Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
  de réir: Catherine Mease, et al.
  Foilsithe / Cruthaithe: (2024-02-01)
• The effects of lobbying on the FDA’s recall classification
  de réir: Yifan Zhou
  Foilsithe / Cruthaithe: (2023-06-01)
• Restructuring the FDA’s Food Program: Promises and Pitfalls
  de réir: Sammer Marzouk, et al.
  Foilsithe / Cruthaithe: (2024-10-01)
• Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
  de réir: Kathleen L. Miller, et al.
  Foilsithe / Cruthaithe: (2021-06-01)
• FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
  de réir: Muhammad Mazhar Azam, et al.
  Foilsithe / Cruthaithe: (2024-12-01)